Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
Barron's on MSN12d
Novo Is Ready to Ramp Up GLP-1 Manufacturing Following $11B Factory DealHenrik Wulff, the man in charge of product supply at Novo Nordisk, just spent $11 billion to try to fill ... will operate as ...
Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
GlobalData on MSN12d
Novo Holdings completes Catalent acquisition for $16.5bnThe company aims to enhance its status as a global service provider for the pharmaceutical and biotechnology sectors while ...
Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management.
PETERSBURG – The world’s second-largest pharmaceutical company is taking ownership of AMPAC Fine Chemicals’ Petersburg ...
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback